Daewoong ties up with AI enterprise to expand new drug indications

Tom Smith

Daewoong Pharmaceutical stated Monday it has signed a partnership arrangement with AI-dependent new drug developer, Oncocross. &#13 &#13 Daewoong aims to develop the indications of its new medicine, Enavogliflozin and DWN12088, beneath advancement by grafting them to Oncocross’s gene expression sample-dependent AI platform, RAPTOR AI.  &#13 &#13 The drugmaker programs […]

Daewoong Pharmaceutical stated Monday it has signed a partnership arrangement with AI-dependent new drug developer, Oncocross.

&#13
&#13

Daewoong aims to develop the indications of its new medicine, Enavogliflozin and DWN12088, beneath advancement by grafting them to Oncocross’s gene expression sample-dependent AI platform, RAPTOR AI. 

&#13
&#13

The drugmaker programs to increase the indications of Enavogliflozin, beneath progress as a diabetes treatment, to treat other signs, this sort of as weight problems, heart condition, and kidney disorders, it said.

&#13
&#13

Daewoong Pharmaceutical CEO Jueon Seng-ho (left) and Oncocross CEO Kim Yi-rang signed a partnership agreement at Daewoong’s most important office environment in Samsung-dong, southern Seoul, on Monday. (Daewoong)

&#13
&#13

Daewoong will also search for the possibility of an anticancer drug from DWN12088, a polygenic risk score (PRS) focus on procedure for intractable fibrosis transpiring in the lungs, kidney and pores and skin. 

&#13
&#13

Applying Oncocross’s AI system, Daewoong expects to cut down the drug development procedure sharply, as it can locate the optimal treatment mix. 

&#13
&#13

“The grafting of new drug improvement with AI system has emerged as a new craze,” Daewoong CEO Jeon Seng-ho claimed. “We be expecting to establish a prosperous pipeline product via an open collaboration of our new drug developing capacity and Oncocross’s bioinformatics-based mostly AI system.”

&#13
&#13

Oncocross CEO Kim Yi-rang also explained, “We will consider to make absolutely sure that our AI technology and Daewoong’s new drug development capabilities modify the current paradigm of drug enhancement. We will broaden the cooperative marriage with other pharmaceutical providers, too.”
&#13
 

Next Post

Cadila Healthcare announces settlement of patent litigation for generic Revlimid in US

&#13 Cadila Health care and its subsidiary Zydus Pharmaceuticals (United states) Inc. have achieved an settlement with Celgene Corporation (Celgene), a wholly owned subsidiary of Bristol Myers Squibb relating to patents for Revlimid (lenalidomide). As section of the settlement, the get-togethers will file consent judgments with the United States District […]

Subscribe US Now